A call to action: new treatment options provide even more reasons to intervene in tobacco dependence.
Anthenelli
Robert M
RM
Addiction Sciences Division, University of Cincinnati College of Medicine and Cincinnati Veterans Affairs Medical Center, OH, USA. robert.anthenelli@uc.edu
D001552:Benzazepines / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000209:etiology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D050171:Dyslipidemias / Q000150:complications; D006801:Humans; D009765:Obesity / Q000150:complications; D010880:Piperidines / Q000627:therapeutic use; D015995:Prevalence; D011720:Pyrazoles / Q000627:therapeutic use; D011810:Quinoxalines / Q000627:therapeutic use; D000077285:Rimonabant; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects / Q000453:epidemiology*; D016540:Smoking Cessation / Q000706:statistics & numerical data*; D014029:Tobacco Use Disorder / Q000188:drug therapy / Q000523:psychology / Q000628:therapy*; D000068580:Varenicline
D001552:Benzazepines; D010880:Piperidines; D011720:Pyrazoles; D011810:Quinoxalines; D000077285:Rimonabant; D000068580:Varenicline